<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>General anesthesia: Intravenous induction agents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">General anesthesia: Intravenous induction agents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">General anesthesia: Intravenous induction agents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian Bravenec, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Girish P Joshi, MB, BS, MD, FFARCSI</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ron M Walls, MD, FRCPC, FAAEM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H721183963"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a>, <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, and <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> are the intravenous (IV) sedative-hypnotic agents commonly used to induce general anesthesia (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>), while adjuvant agents (eg, opioids, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a>, and volatile anesthetics) are often used to supplement the effects of the primary sedative-hypnotic induction agent (<a class="graphic graphic_table graphicRef106541" href="/d/graphic/106541.html" rel="external">table 2</a>). This topic discusses advantages and beneficial effects, disadvantages and adverse effects, pharmacokinetics, dosing considerations, and typical uses of each of the sedative-hypnotic and adjuvant agents used to induce general anesthesia. </p><p>Our overview of techniques for induction of general anesthesia with IV or inhalation anesthetics (or combinations of these agents) including the selection of specific agents is found in a separate topic. (See  <a class="medical medical_review" href="/d/html/94135.html" rel="external">"Induction of general anesthesia: Overview"</a>.)</p><p class="headingAnchor" id="H4070595924"><span class="h1">DOSING CONSIDERATIONS</span><span class="headingEndMark"> — </span>All available sedative-hypnotic IV induction agents (eg, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a>, <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">methohexital</a>) are capable of achieving adequate depth of general anesthesia. After IV injection, these induction agents have rapid onset due to their high lipid solubility allowing penetration of the blood-brain barrier, and the high proportion of the cardiac output (CO) that perfuses the brain (the effect site). </p><p>Typically, one or more adjuvant medications are also administered to achieve the desired initial depth of anesthesia and induction conditions [<a href="#rid1">1</a>]. (See <a class="local">'Adjuvant agents'</a> below and  <a class="medical medical_review" href="/d/html/94135.html" rel="external">"Induction of general anesthesia: Overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estimating dose</strong> – Fixed dosing regimens are not recommended. Initial doses of IV sedative-hypnotic and adjuvant agents are individualized. Factors affecting dosing include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Body weight – dosing is based on adjusted body weight, particularly in patients with obesity (<a class="graphic graphic_table graphicRef90705" href="/d/graphic/90705.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/14932.html" rel="external">"Anesthesia for the patient with obesity", section on 'Dosing anesthetic drugs'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Known adverse effects (eg, hypotension, respiratory depression) of the induction agent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individual patient variations in pharmacodynamics (ie, what the drug does to the patient) and pharmacokinetics (ie, what the patient does to the drug). For example, induction doses are reduced in patients with:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hemodynamic abnormalities due to hypovolemia, vasodilation, or myocardial dysfunction </p><p class="bulletIndent3"><span class="glyph">-</span>Impaired renal or hepatic function</p><p class="bulletIndent3"><span class="glyph">-</span>Advanced age and/or frailty (see  <a class="medical medical_review" href="/d/html/14931.html" rel="external">"Anesthesia for the older adult", section on 'Selection and dosing of anesthetic agents'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Compromised mental status (dementia, intoxication, metabolic derangements)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Whether adjuvant drugs are coadministered – When agents from different classes are combined, the hypnotic effects are often synergistic rather than merely additive. For example, opioids allow dose reduction of the selected sedative-hypnotic agent. (See <a class="local">'Adjuvant agents'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Whether a combination of sedative-hypnotic induction agents is used – We do not use combinations of sedative-hypnotic agents in our practice. Some clinicians do combine <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> with either <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> or <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> in an attempt to mitigate the hypotensive effects of propofol. However, evidence for advantages of such combinations is limited. One study in healthy patients (ASA physical status 1 or 2) found that a combination of propofol and ketamine improved hemodynamic stability [<a href="#rid2">2</a>]. A separate study by these investigators did not find any benefit of this combination in critically ill patients [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2">Also, the optimal dosing regimen for each component of the combination (ie, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> and <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> or <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>) is unclear. There is significant heterogeneity among studies in dosing for each agent (eg, propofol, ketamine, etomidate), as well as whether an opioid or other adjunct agent was used during induction. Also, the influence of such combinations on adverse effects of the other sedative-hypnotic agent was not evaluated in most studies (eg, ketamine [psychotomimetic effects] or etomidate [adrenocortical suppression]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Titrating doses</strong> –<strong> </strong>Drug doses are typically titrated in increments, with a brief time between doses (eg, 30 seconds), unless a rapid sequence induction and intubation technique is selected. The following general principles are useful:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continually assess the state of consciousness (eg, responses to voice or tactile stimulation such as the lash reflex or placement of an oral airway) as well as heart rate (HR) and blood pressure (BP). While the time interval to maximum hypnotic effect is often longer than the titration interval, the onset of sedative/hypnotic effects is noticeable well before the peak effect. This should help avoid overdosing of the sedative-hypnotic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although some clinicians attempt to use processed electroencephalogram (EEG) monitoring to assess anesthetic depth (eg, bispectral index [BIS] or entropy signal changes), there is a lag time of at least 30 seconds required for EEG signal processing. This lag between the patient's current state of consciousness and the displayed EEG value limits utility of this monitor during induction [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Induction agents cannot be titrated to effect if rapid sequence induction and intubation is necessary. Reasonable doses of the selected agent(s) are based on the patient's condition and planned coadministration of one or more adjuvant agents. If necessary, additional doses of the induction anesthetic, adjuvant agents, or vasoactive agents may be administered to treat hemodynamic aberrations before induction or immediately after successful intubation. (See <a class="local">'Opioids'</a> below.)</p><p></p><p class="headingAnchor" id="H2269410"><span class="h1">PROPOFOL</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> is the most commonly used IV induction agent (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>). Its primary mechanism of action is activation of the gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>) receptor complex, the chief inhibitory neurotransmitter of the central nervous system. Propofol is also an antagonist of the N-methyl-D-aspartate (NMDA) receptor.</p><p class="headingAnchor" id="H2657717339"><span class="h2">Advantages and beneficial effects</span><span class="headingEndMark"> — </span>Advantages of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> include (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid onset (30 to 45 seconds) and rapid recovery. The dose-dependent effect of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> on pupillary diameter correlates with bispectral index (BIS) values [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiemetic properties. <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> is a good choice for patients at increased risk for postoperative nausea and vomiting [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/16849.html" rel="external">"Postoperative nausea and vomiting"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antipruritic properties. <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> is a good choice for patients who will receive opioids, which often cause pruritus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upper airway and bronchodilatory properties with decreased airway resistance [<a href="#rid7">7,8</a>]. <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> is useful for induction in patients with bronchospasm and asthma [<a href="#rid8">8,9</a>]. (See  <a class="medical medical_review" href="/d/html/94358.html" rel="external">"Anesthesia for adult patients with asthma", section on 'Anesthetic agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system effects that may be advantageous in patients with brain injury including (see  <a class="medical medical_review" href="/d/html/94283.html" rel="external">"Anesthesia for patients with acute traumatic brain injury", section on 'Choice of anesthetic agents'</a> and  <a class="medical medical_review" href="/d/html/94284.html" rel="external">"Anesthesia for intracranial neurovascular procedures in adults"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anticonvulsant properties.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose-dependent decreases in cerebral metabolic rate of oxygen consumption and consequent reduction in cerebral blood flow and intracranial pressure (ICP) are beneficial if mean arterial pressure and cerebral perfusion pressure are maintained [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suitability for patients with renal and/or hepatic insufficiency [<a href="#rid11">11-17</a>]. (See  <a class="medical medical_review" href="/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Induction'</a> and  <a class="medical medical_review" href="/d/html/91242.html" rel="external">"Anesthesia for the patient with liver disease", section on 'Sedative hypnotics'</a>.)</p><p></p><p class="headingAnchor" id="H576335320"><span class="h2">Disadvantages and adverse effects</span><span class="headingEndMark"> — </span>Potential adverse effects of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> include (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Dose-dependent hypotension. This is due primarily to venous and arterial dilation, as well as decreased contractility [<a href="#rid18">18-23</a>]. Heart rate (HR) is minimally affected because the baroreceptor reflex is blunted. However, systolic blood pressure (BP) decreases to &lt;90 mmHg in 16 percent of patients [<a href="#rid20">20</a>]. Severe hypotension may occur in patients who are hypovolemic or hemodynamically compromised, as well as in older patients [<a href="#rid18">18</a>]. (See <a class="local">'Dosing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dose-dependent respiratory depression (decreases in respiratory rate, tidal volume, and ventilatory responses to hypoxia and hypercarbia) and apnea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain on injection occurring in approximately two-thirds of patients due to venous irritation caused by <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> itself rather than its lipid emulsion [<a href="#rid24">24</a>]. Propofol is typically coadministered with <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> and/or an opioid to minimize pain on injection [<a href="#rid24">24-26</a>] (see <a class="local">'Lidocaine'</a> below and <a class="local">'Opioids'</a> below). Also, administration into a larger vein may decrease discomfort. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contamination risk. Despite the addition of antimicrobials, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> preparations support rapid bacterial growth due to the lipid emulsion containing egg lecithin, glycerol, and soybean oil. Fever, infection, sepsis, and death have been reported [<a href="#rid27">27</a>]. Risk is minimized by:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Using an aseptic technique in drug preparation</p><p class="bulletIndent2"><span class="glyph">•</span>Avoiding multidose use from a single vial for more than one patient </p><p class="bulletIndent2"><span class="glyph">•</span>Discarding opened <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> after six hours</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rare allergic reactions [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Hypnotic induction agents'</a> and  <a class="medical medical_review" href="/d/html/2406.html" rel="external">"Management of food allergy: Avoidance", section on 'Lipid emulsions'</a>.)</p><p></p><p class="headingAnchor" id="H1745064393"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span>Coadministration of one or more adjuvant anesthetic agents acting on other receptor types, including opioids, benzodiazepines, and volatile anesthetics, may produce synergistic anesthetic effects as well as increase the potential for adverse effects (eg, hypotension). Thus, reduction of the <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> dose is prudent [<a href="#rid1">1,29</a>]. (See <a class="local">'Adjuvant agents'</a> below and <a class="local">'Dosing'</a> below.)</p><p class="headingAnchor" id="H165838481"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> is highly lipid soluble with formulation in an aqueous emulsion containing egg phosphatide, soybean oil, and glycerol. Its onset of action is very rapid due to high lipid-solubility. The half-life of equilibration between plasma and effect site (the brain) is 1.5 to 2.6 minutes [<a href="#rid30">30</a>]. Duration of action is short (two to eight minutes), as propofol is rapidly redistributed from the brain into a very large volume of distribution in other tissues (3 to 12 L/kg) [<a href="#rid31">31</a>].</p><p>Most of the drug is conjugated in the liver and the resulting inactive metabolites are eliminated by the kidneys. Clearance of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> is very rapid (20 to 30 mL/kg/minute), in excess of liver blood flow, suggesting extrahepatic metabolism [<a href="#rid11">11</a>]. Although propofol has a long terminal elimination half-life of 4 to 30 hours, actual plasma concentrations remain low throughout this time period after administration of a typical induction dose [<a href="#rid32">32,33</a>].</p><p class="headingAnchor" id="H1872411706"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>The induction dose of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> for general anesthesia is 1 to 2.5 mg/kg (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>) [<a href="#rid34">34</a>]. </p><p>Dose-dependent hypotension is avoided by reducing the initial dose and titrating <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> in increments, particularly in the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>Older age (suggested dose is 1 to 1.5 mg/kg). Dose reduction is prudent due to changes in pharmacodynamics, as well as changes in clearance and central volume of distribution [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/14931.html" rel="external">"Anesthesia for the older adult", section on 'Intravenous anesthetic and adjuvant agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypovolemia (eg, sepsis, hemorrhage) or myocardial dysfunction (suggested dose is ≤1 mg/kg) [<a href="#rid18">18,35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coadministration of one or more adjuvant anesthetic agents acting on other receptor types because of synergistic effects [<a href="#rid1">1,29</a>].</p><p></p><p class="headingAnchor" id="H307136729"><span class="h1">ETOMIDATE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">Etomidate</a> is often selected for anesthetic induction in hemodynamically unstable patients because it causes minimal hemodynamic changes (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>) [<a href="#rid36">36</a>]. It is an imidazole derivative that acts directly on the gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>)<sub> </sub>receptor complex to block neuroexcitation and produce anesthesia.</p><p class="headingAnchor" id="H3248597381"><span class="h2">Advantages and beneficial effects</span><span class="headingEndMark"> — </span>Advantages of <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> include (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Superior hemodynamic stability without vasodilation, myocardial depression, or decreases in sympathetic tone [<a href="#rid37">37</a>]. Blood pressure (BP), heart rate (HR), and cardiac output (CO) typically remain stable, but may increase if airway manipulation or pain causes sympathetic stimulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most favorable therapeutic index (ratio of median lethal dose [LD<sub>50</sub>] to median effective dose [EC<sub>50</sub>]) compared with other anesthetic induction agents [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid onset and recovery, similar to <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system effects that may be advantageous, particularly in hemodynamically unstable patients with head injury or stroke, including dose-dependent decreases in cerebral metabolic rate of oxygen consumption and consequent reduction in cerebral blood flow and intracranial pressure (ICP). These effects are beneficial if mean arterial pressure and cerebral perfusion pressure are adequately maintained. (See  <a class="medical medical_review" href="/d/html/94283.html" rel="external">"Anesthesia for patients with acute traumatic brain injury", section on 'Choice of anesthetic agents'</a> and  <a class="medical medical_review" href="/d/html/271.html" rel="external">"Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Head injury or stroke'</a>.): </p><p></p><p class="headingAnchor" id="H262499028"><span class="h2">Disadvantages and adverse effects</span><span class="headingEndMark"> — </span>Potential adverse effects of <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> include (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>High incidence (approximately 30 percent) of postoperative nausea and vomiting [<a href="#rid38">38,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain on injection occurring in up to 80 percent of patients, although typically less painful than <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> injection [<a href="#rid38">38,40</a>]. This is caused by venous irritation due to the low pH (6.9) of the 35 percent propylene glycol used in <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> formulations [<a href="#rid40">40</a>]. Pain is minimized or eliminated when etomidate is injected into a larger or central vein. Also, coadministration of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> or an opioid may reduce pain, although these adjuvant agents are typically omitted in hemodynamically unstable patients. (See <a class="local">'Lidocaine'</a> below and <a class="local">'Opioids'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dose-related involuntary myoclonic movements, occurring in 50 to 80 percent of patients if <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> is administered without any neuromuscular blocking agent [<a href="#rid38">38,41-44</a>]. These jerking movements are due to subcortical disinhibition unrelated to cortical seizure activity [<a href="#rid40">40</a>]. Although coadministration of an opioid or benzodiazepine can attenuate myoclonus, these adjuvant agents are typically omitted in hemodynamically unstable patients [<a href="#rid41">41-44</a>]. (See <a class="local">'Opioids'</a> below and <a class="local">'Midazolam'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Undesirable increases in BP, HR, and ICP that may occur during laryngoscopy and endotracheal intubation due to sympathetic stress responses. An opioid and/or <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> can be administered to attenuate these increases when appropriate (eg, elevated ICP, coronary artery disease, or aneurysm [cerebral or systemic] in a hemodynamically stable patient). (See <a class="local">'Opioids'</a> below and <a class="local">'Lidocaine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild increases in airway resistance [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transient acute adrenal insufficiency. Following a single induction dose of <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, reversible inhibition of 11-beta-hydroxylase (which converts 11-deoxycortisol to cortisol) causes adrenocortical suppression lasting &lt;24 hours in both healthy and critically ill patients [<a href="#rid45">45-54</a>]. Cortisol plasma concentrations do not necessarily fall below the normal range, but may not appropriately rise in response to surgical stimulation after etomidate administration [<a href="#rid52">52,53</a>]. Although the clinical significance of this transient inhibition of cortisol biosynthesis is uncertain, the preponderance of evidence suggests that etomidate is not harmful if used as a single dose to induce anesthesia in relatively healthy patients. Studies include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Noncardiac surgery – A retrospective study in patients undergoing noncardiac surgery reported a higher 30-day mortality in 2144 patients receiving <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> for induction compared with 5233 propensity-matched patients receiving <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> (odds ratio [OR] 2.5, 98% CI 1.9-3.4) [<a href="#rid55">55</a>]. Important confounding covariates in this study include frequent selection of etomidate for induction in patients who are critically ill.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac surgery:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Retrospective studies in patients undergoing cardiac surgery have not noted increased mortality after use of <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> for anesthetic induction compared with other induction agents [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One prospective study in patients undergoing coronary artery bypass grafting noted no differences in mortality, perioperative vasopressor requirements, time to extubation, or length of intensive care unit stay after use of <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> compared with <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> for induction [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Emergency endotracheal intubation in critically ill patients:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A 2015 systematic review of eight randomized trials concluded that <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> was not associated with increased mortality compared with any other induction agent in critically ill patients (OR 1.17, 95% CI 0.86-1.60) [<a href="#rid50">50</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Another 2015 meta-analysis of randomized controlled trials and observational studies in critically ill patients diagnosed with sepsis noted that a single dose of <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> did not increase mortality compared with those not receiving etomidate [<a href="#rid58">58</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A subsequently published randomized trial compared induction with <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> versus <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> in 801 critically ill patients did note lower survival on day 7 in the etomidate group (77.3 versus 85.1 percent), but no difference by day 28 (64.1 versus 66.8 percent) [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Emergency endotracheal intubation in patients with septic shock:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A 2012 meta-analysis of randomized controlled trials and observational studies in patients with frank septic shock suggests that use of <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> may increase risk for development of adrenal insufficiency and mortality [<a href="#rid60">60</a>]. Thus, we usually select <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> rather than etomidate in patients with septic shock. (See  <a class="medical medical_review" href="/d/html/94164.html" rel="external">"Intraoperative management of shock in adults", section on 'Septic shock'</a>.)</p><p></p><p class="bulletIndent3">Furthermore, if <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> is used in a septic patient who subsequently develops refractory hypotension, we administer a stress dose of a glucocorticoid (eg, IV <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> 100 mg or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 4 mg). However, we do not administer prophylactic glucocorticoids in most settings. In one retrospective study that included 582 patients who received intraoperative steroids after anesthetic induction with etomidate (typically dexamethasone at a median dose of 6 mg), mortality was not different from that of 1023 propensity-matched patients who received etomidate but no steroids [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/1654.html" rel="external">"Glucocorticoid therapy in septic shock in adults"</a>.)</p><p></p><p class="bulletIndent3">In an individual patient with suspected adrenal insufficiency (eg, those receiving chronic glucocorticoid therapy) but without evidence of septic shock, the risk of further cortisol suppression caused by <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> is balanced against risk of hemodynamic instability caused by induction with other agents. Notably, we do not administer multiple bolus doses or infusions of etomidate.</p><p></p><p class="headingAnchor" id="H242460226"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span>Coadministration of one or more adjuvant anesthetic agents acting on other receptor types (eg, opioids, benzodiazepines, volatile anesthetics) may produce synergistic anesthetic effects [<a href="#rid1">1</a>]. (See <a class="local">'Adjuvant agents'</a> below and <a class="local">'Dosing'</a> below.)</p><p class="headingAnchor" id="H3348275065"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">Etomidate</a> has a rapid onset, similar to <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> [<a href="#rid62">62</a>]. The half-life of equilibration between plasma and effect site (the brain) is 1.6 minutes [<a href="#rid63">63</a>]. Duration of action is short (3 to 12 minutes) due to rapid redistribution from the brain to other tissues. The volume of distribution is 2.5 to 4.5 L/kg [<a href="#rid62">62-64</a>].</p><p>The main route of metabolism is ester hydrolysis in the liver resulting in pharmacologically inactive metabolites. Clearance of <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> is high (18 to 25 mL/kg/minute). Terminal elimination half-life is three to five hours. </p><p class="headingAnchor" id="H4201415421"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>The induction dose of <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> for general anesthesia is 0.15 to 0.3 mg/kg (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>) [<a href="#rid65">65</a>]. To minimize inhibition of cortisol biosynthesis, repeated bolus doses of etomidate are usually avoided. (See <a class="local">'Disadvantages and adverse effects'</a> above.)</p><p>Although the dose of <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> is not typically adjusted to avoid hemodynamic side effects, it is prudent to reduce the initial dose to 0.1 to 0.15 mg/kg in patients with hemodynamic instability, particularly in those with severe hypotension or shock. Also, dose may also be adjusted if adjuvant anesthetic agents are administered during induction [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/94164.html" rel="external">"Intraoperative management of shock in adults", section on 'Induction'</a> and <a class="local">'Adjuvant agents'</a> below.)</p><p class="headingAnchor" id="H2269465"><span class="h1">KETAMINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a> may be selected to induce anesthesia in a hypotensive patient as it typically increases blood pressure (BP), heart rate (HR), and cardiac output (CO) by increasing sympathetic tone (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>) [<a href="#rid66">66-68</a>]. The primary mechanism of action is noncompetitive antagonism of glutamate at the N-methyl-D-aspartate (NMDA) receptor-cation channel complex, causing neuroinhibition and anesthesia [<a href="#rid69">69</a>]. Also, ketamine excites opioid receptors within the insular cortex, putamen, and thalamus, thereby producing analgesia.</p><p>Unlike other anesthetic induction agents, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> is structurally similar to phencyclidine and produces dissociative anesthesia (profound analgesia while appearing disconnected from surroundings) [<a href="#rid70">70</a>]. The term "dissociative," is also used to describe the electroencephalographic (EEG) effects of ketamine because EEG activity in the hippocampus is dissociated from that in the thalamo-neocortical system. An association between the dissociative and analgesic effects of ketamine is likely [<a href="#rid71">71</a>]. </p><p class="headingAnchor" id="H887839396"><span class="h2">Advantages and beneficial effects</span><span class="headingEndMark"> — </span>Advantages of <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> include (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>) [<a href="#rid72">72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increases in BP, HR, and CO in most patients due to increased sympathetic tone [<a href="#rid66">66-68</a>], and reduced vasodilation due to inhibition of production of vascular nitric oxide [<a href="#rid73">73</a>]. However, these increases in BP and CO do not occur if presynaptic catecholamine stores have been depleted. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bronchodilatory properties. Thus, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> is useful in patients with bronchospasm and/or asthma, particularly if emergency intubation for severe bronchospasm is necessary [<a href="#rid74">74,75</a>]. (See  <a class="medical medical_review" href="/d/html/94358.html" rel="external">"Anesthesia for adult patients with asthma", section on 'Anesthetic agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance of airway reflexes and respiratory drive. Thus, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> is useful when maintenance of spontaneous respiration is desirable [<a href="#rid67">67,76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Profound analgesic properties, even in sub-hypnotic doses. Thus, administration of an opioid adjuvant agent is unnecessary during anesthetic induction (see <a class="local">'Opioids'</a> below). Also, intraoperative administration of <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> reduces postoperative opioid consumption in patients with chronic pain, opioid tolerance, or hyperalgesia [<a href="#rid77">77-80</a>]. (See  <a class="medical medical_review" href="/d/html/133187.html" rel="external">"Nonopioid pharmacotherapy for acute pain in adults", section on 'Ketamine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suitability for patients with renal and/or hepatic insufficiency without dose adjustments. (See <a class="local">'Dosing'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid onset and recovery after IV administration, similar to <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternative routes of administration when necessary. Intramuscular (IM) injection is used in rare cases when IV access is impractical or inadvertently lost during induction (eg, in a severely agitated patient). Oral or rectal administration is also feasible for children.</p><p></p><p class="headingAnchor" id="H2269513"><span class="h2">Disadvantages and adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a> has the following potential adverse effects (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>) [<a href="#rid72">72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a>'s unique ability to stimulate catecholamine receptors may be beneficial in hypotensive patients, the resulting increases in BP, HR, contractility, and pulmonary arterial pressure (PAP) may be detrimental in selected patient groups [<a href="#rid81">81-83</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Ischemic heart disease due to potential for imbalance between myocardial oxygen supply and demand [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/90616.html" rel="external">"Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Induction'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypertension due to further undesirable increases in BP. (See  <a class="medical medical_review" href="/d/html/94355.html" rel="external">"Anesthesia for patients with hypertension"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pulmonary hypertension or right heart dysfunction due to further increases in PAP. (See  <a class="medical medical_review" href="/d/html/94362.html" rel="external">"Anesthesia for noncardiac surgery in patients with pulmonary hypertension or right heart failure", section on 'Induction and maintenance of general anesthesia'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cocaine use (known or suspected), as <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> may potentiate the cardiovascular toxicity of cocaine leading to myocardial ischemia, arrhythmias, and pulmonary hypertension [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intrinsic mild myocardial depressant properties that are normally overcome by increased sympathetic tone, but may become apparent if catecholamine reserves are depleted (eg, patients with shock due to severe sepsis, hypovolemia, or cardiogenic causes; patients chronically using cocaine) [<a href="#rid86">86</a>]. Since myocardial depressant effects are dose-related, induction doses are reduced in any patient with profound hypotension (mean arterial pressure &lt;50 mmHg) or shock. (See <a class="local">'Dosing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Psychotomimetic effects that include hallucinations, nightmares, and vivid dreams occurring during and shortly after emergence from anesthesia [<a href="#rid87">87-89</a>]. Prior administration of a benzodiazepine may minimize these effects [<a href="#rid90">90</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Double vision; blurry vision.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sympathomimetic effects that increase cerebral blood flow and intracranial pressure (ICP) in spontaneously breathing patients. (See  <a class="medical medical_review" href="/d/html/93391.html" rel="external">"Anesthesia for craniotomy in adults", section on 'Induction of anesthesia'</a> and  <a class="medical medical_review" href="/d/html/94283.html" rel="external">"Anesthesia for patients with acute traumatic brain injury", section on 'Choice of anesthetic agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Possible increased cerebral metabolism with increased sympathetic stimulation [<a href="#rid91">91</a>]. However, some clinical studies suggest that <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> does not significantly interfere with cerebral metabolism [<a href="#rid81">81,92,93</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unique EEG effects that may result in misinterpretation of processed EEG values (eg, the bispectral index [BIS]). (See  <a class="medical medical_review" href="/d/html/91216.html" rel="external">"Neuromonitoring in surgery and anesthesia", section on 'Intravenous agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with cognitive dysfunction as it might exacerbate this in the postoperative period [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Airway effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased salivation and upper airway secretions.</p><p class="bulletIndent2"><span class="glyph">•</span>Minimal attenuation of airway reflexes.</p><p></p><p class="headingAnchor" id="H1385138965"><span class="h2">Drug-drug interactions</span></p><p class="bulletIndent1"><span class="glyph">●</span>Potentiation of the cardiovascular toxicity of cocaine that may lead to myocardial ischemia, arrhythmias, and pulmonary hypertension [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/139188.html" rel="external">"Anesthesia for patients with substance use disorder or acute intoxication", section on 'Cocaine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additive effects with chronically administered medications that have noradrenergic effects (eg, amphetamines, norepinephrine reuptake inhibitors such as tricyclic antidepressants) [<a href="#rid95">95</a>]. (See  <a class="medical medical_review" href="/d/html/139188.html" rel="external">"Anesthesia for patients with substance use disorder or acute intoxication", section on 'Amphetamines and similar agents'</a> and  <a class="medical medical_review" href="/d/html/139188.html" rel="external">"Anesthesia for patients with substance use disorder or acute intoxication", section on 'Hallucinogens and dissociative drugs'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Synergistic anesthetic effects if coadministered with a volatile inhalation anesthetic agent during induction. Thus, the induction dose of <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> may be reduced [<a href="#rid1">1</a>]. However, no dose reduction is necessary when ketamine is coadministered with other IV adjuvant agents. (See <a class="local">'Adjuvant agents'</a> below and <a class="local">'Dosing'</a> below.)</p><p></p><p class="headingAnchor" id="H3610684087"><span class="h2">Pharmacokinetics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV administration</strong> – <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a> has a rapid onset (approximately one minute) [<a href="#rid96">96</a>]. Volume of distribution of ketamine is approximately 3 L/kg [<a href="#rid97">97,98</a>]. Duration of action is 10 to 20 minutes because ketamine has several active metabolites after hepatic metabolism [<a href="#rid89">89,99</a>]. Norketamine, the primary metabolite, has significant pharmacodynamic effects similar to those of ketamine, but with one-tenth to one-third of ketamine's potency. Thus, norketamine contributes to total time until return of consciousness after an induction dose (9 to 20 minutes), and also contributes to analgesic effects, which last longer than the anesthetic effects [<a href="#rid97">97,98</a>].</p><p></p><p class="bulletIndent1">Clearance of <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> is similar to liver blood flow (15 to 20 mL/kg/minute). Neither renal nor moderate hepatic dysfunction has a clinically significant effect on ketamine clearance. The terminal elimination half-life is two to three hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IM administration</strong> – Onset of action after IM administration is approximately 15 to 30 minutes, which is much slower than onset after IV induction [<a href="#rid97">97-99</a>]. Peak plasma concentrations occur after 15 to 30 minutes and are similar to concentrations after IV administration of 2 mg/kg [<a href="#rid100">100</a>]. Due to variable absorption from muscle tissue, clinical duration of action may be significantly longer after IM administration compared with IV administration [<a href="#rid100">100</a>].</p><p></p><p class="headingAnchor" id="H1177223154"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>The IV induction dose of <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> for general anesthesia is 1 to 2 mg/kg IV (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>). The IM induction dose is 4 to 6 mg/kg.</p><p><a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a> dosing is not usually adjusted to avoid hemodynamic side effects (see <a class="local">'Advantages and beneficial effects'</a> above). Also, dose reduction is unnecessary when ketamine is coadministered with other IV adjuvant agents since these agents have only additive or infra-additive (antagonistic) effects when combined with ketamine, rather than synergistic effects (see <a class="local">'Adjuvant agents'</a> below). However, a lower initial dose of 0.5 to 1 mg/kg is prudent for patients with severe hypotension or shock since catecholamine reserves may be depleted. (See  <a class="medical medical_review" href="/d/html/94164.html" rel="external">"Intraoperative management of shock in adults", section on 'Induction'</a>.)</p><p class="headingAnchor" id="H181245995"><span class="h1">METHOHEXITAL</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">Methohexital</a> is an oxybarbiturate sedative-hypnotic induction agent that activates seizure foci; thus, it is ideal for patients undergoing electroconvulsive therapy (ECT) (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults", section on 'Anesthesia technique'</a>.)</p><p>Similar to <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, barbiturates such as <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">methohexital</a> facilitate inhibitory neurotransmission by enhancing gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>) receptor function and direct activation of chloride channels, thereby mimicking the action of GABA. Methohexital also inhibits excitatory neurotransmission via glutamate and nicotinic acetylcholine receptors.</p><p class="headingAnchor" id="H1734965617"><span class="h2">Advantages and beneficial effects</span><span class="headingEndMark"> — </span>The unique ability of <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">methohexital</a> to activate seizure foci is ideal for ECT procedures.</p><p class="headingAnchor" id="H356478373"><span class="h2">Disadvantages and adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">Methohexital</a> has the following potential adverse effects (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>The activation of seizure foci is a disadvantage in patients with seizure disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dose-dependent decreases in blood pressure (BP) due to venodilation and decreased myocardial contractility result in reflex increases in heart rate (HR) because baroreceptor reflexes remain intact. Although reductions in BP after <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">methohexital</a> administration are typically less than after <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> administration (see <a class="local">'Disadvantages and adverse effects'</a> above), we titrate the induction dose in patients likely to develop hypotension (eg, older patients), and in those who may develop imbalances in myocardial oxygen supply versus demand. (See  <a class="medical medical_review" href="/d/html/14931.html" rel="external">"Anesthesia for the older adult", section on 'Cardiovascular system'</a> and  <a class="medical medical_review" href="/d/html/90616.html" rel="external">"Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dose-dependent respiratory depression with decreases in respiratory rate, tidal volume, and ventilatory response to hypoxia and hypercarbia that may lead to apnea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain on injection occurring in up to 60 percent of patients [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Involuntary myoclonic movements (similar to <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> (see <a class="local">'Disadvantages and adverse effects'</a> above)), as well as hiccups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exacerbation of acute intermittent porphyria, which occurs due to induction of hepatic enzymes involved in heme biosynthesis [<a href="#rid102">102</a>]. Thus, <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">methohexital</a> is contraindicated in patients with porphyria, as are other barbiturates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rare anaphylactic reactions. (See  <a class="medical medical_review" href="/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Hypnotic induction agents'</a>.)</p><p></p><p class="headingAnchor" id="H2613619630"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span>Coadministration of one or more adjuvant anesthetic agents acting on other receptor types (eg, opioids, benzodiazepines, volatile anesthetics) may produce synergistic anesthetic effects. Thus, reduction of the <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">methohexital</a> dose is prudent. (See <a class="local">'Adjuvant agents'</a> below and <a class="local">'Dosing'</a> below.)</p><p class="headingAnchor" id="H2621093711"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">Methohexital</a> has a rapid onset (10 to 30 seconds), and a duration of action lasting 5 to 10 minutes. Volume of distribution is approximately 2 L/kg. Metabolism occurs in the liver and clearance is somewhat lower than other sedative-hypnotic induction agents. The elimination half-life is approximately four hours.</p><p class="headingAnchor" id="H3270637583"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>The induction dose of <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">methohexital</a> is 1 to 1.5 mg/kg. To avoid dose-dependent hypotension, we administer a dose at the lower end of this range, titrated in increments, in patients who are older or have medical comorbidities, and when supplemental adjuvant anesthetic agents are coadministered. (See <a class="local">'Adjuvant agents'</a> below.)</p><p class="headingAnchor" id="H2272654275"><span class="h1">ADJUVANT AGENTS</span><span class="headingEndMark"> — </span>One or more adjuvant IV agents are often administered during induction of general anesthesia to blunt the sympathetic stress response and cough reflex during laryngoscopy and intubation, minimize pain due to injection of irritating induction agents, and reduce the primary sedative-hypnotic dose. The most common selections are a short-acting opioid, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, or a benzodiazepine such as <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> or <a class="drug drug_general" data-topicid="128915" href="/d/drug information/128915.html" rel="external">remimazolam</a> (<a class="graphic graphic_table graphicRef106541" href="/d/graphic/106541.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/94135.html" rel="external">"Induction of general anesthesia: Overview", section on 'Techniques and anesthetic agents'</a>.)</p><p class="headingAnchor" id="H240924670"><span class="h2">Opioids</span><span class="headingEndMark"> — </span>Short-acting opioids are the most commonly used adjuvant agents during induction of general anesthesia (<a class="graphic graphic_table graphicRef106541" href="/d/graphic/106541.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Opioid use as an adjuvant agent'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages during induction</strong> (See  <a class="medical medical_review" href="/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suppression of airway reflexes that result in coughing and/or bronchospasm during laryngoscopy and endotracheal intubation [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Attenuation of the stress responses to laryngoscopy and intubation that would otherwise result in tachycardia and hypertension [<a href="#rid104">104-106</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduction of pain caused by IV injection of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">methohexital</a>, or some muscle relaxants, if administered approximately one minute before injection of the irritating agent [<a href="#rid25">25,26,107-110</a>]. Notably, optimal pain reduction may be achieved with <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> alone or a combination of lidocaine plus an opioid [<a href="#rid109">109</a>]. (See <a class="local">'Lidocaine'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supplementation of sedation, which reduces dose requirements for the sedative-hypnotic induction agent by 40 to 70 percent [<a href="#rid111">111-115</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential adverse effects</strong> (See  <a class="medical medical_review" href="/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Prevention and management of adverse opioid effects'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exacerbation of hypotension induced by administration of sedative-hypnotic agents such as <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, which may be mitigated by dose reduction of the sedative-hypnotic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bradycardia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose-dependent respiratory depression and/or apnea, a side effect of all commonly used opioids. If laryngeal mask airway insertion with subsequent spontaneous ventilation is planned, some clinicians omit opioid administration during the induction sequence to avoid a period of postinduction apnea.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postoperative adverse effects such as nausea and vomiting, ileus, constipation, urinary retention, pruritus, delirium, acute tolerance, or hyperalgesia in the postoperative period are more likely if large or additional opioid doses are administered during the maintenance phase of general anesthesia. (See  <a class="medical medical_review" href="/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Analgesic component: Opioid agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Routine induction with endotracheal intubation - Typical doses for each of the opioids that may be used during routine induction of anesthesia are noted in the tables (<a class="graphic graphic_table graphicRef111779" href="/d/graphic/111779.html" rel="external">table 4</a>). To avoid adverse effects, dose reduction is prudent for older adults, those with hemodynamic instability, or if other anesthetic or adjuvant agents are coadministered.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">Remifentanil</a> intubation technique - When remifentanil is used for rapid sequence induction and intubation, an induction dose of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> is typically administered first, followed by remifentanil 3 to 5 mcg/kg together with <a class="drug drug_general" data-topicid="9114" href="/d/drug information/9114.html" rel="external">ephedrine</a> 10 mg (<a class="graphic graphic_table graphicRef111779" href="/d/graphic/111779.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Remifentanil intubation technique'</a> and  <a class="medical medical_review" href="/d/html/94214.html" rel="external">"Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Remifentanil intubation'</a>.) </p><p></p><p class="headingAnchor" id="H1973711502"><span class="h2">Lidocaine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">Lidocaine</a> is often administered during induction of general anesthesia (<a class="graphic graphic_table graphicRef106541" href="/d/graphic/106541.html" rel="external">table 2</a>). It is a class 1B anti-arrhythmic agent that works by reversibly binding sodium ion channels and holding them open with a net effect of preventing depolarization.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages during induction</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During inhalation induction of general anesthesia - Suppression of the cough reflex and laryngospasm during laryngoscopy and intubation [<a href="#rid116">116-125</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased incidence of bronchospasm due to reduced airway responsiveness to noxious stimuli and to drugs that cause bronchospasm, despite an increase in airway tone [<a href="#rid126">126-128</a>]. (See  <a class="medical medical_review" href="/d/html/94358.html" rel="external">"Anesthesia for adult patients with asthma", section on 'Induction of anesthesia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduction of pain caused by IV injection of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">methohexital</a>, or some muscle relaxants when administered into the same vein at a low dose approximately one minute before injection of the irritating agent [<a href="#rid129">129</a>]. A meta-analysis noted that addition of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> to propofol before injection also reduces pain [<a href="#rid26">26</a>]. Lidocaine is typically more effective than an opioid for mitigation of injection pain because of its local anesthetic effect [<a href="#rid24">24-26,107-110,129</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential adverse effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exacerbation of hypotension induced by administration of sedative-hypnotic agents such as <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, which may be mitigated by dose reduction of the sedative-hypnotic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Possibility of lidocaine-induced ventricular rate increases in patients with atrial fibrillation or flutter at doses &gt;50 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Dose is based on the indication:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduction of pain on injection due to <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> or another agent – 30 to 40 mg is administered into the same vein.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Attenuation of airway responses to laryngoscopy and endotracheal intubation - 1 to 1.5 mg/kg is administered as a bolus. However, dose is reduced to 0.5 to 1 mg/kg in older patients, and is usually eliminated or reduced to ≤0.5 mg/kg in patients with hemodynamic instability.</p><p></p><p class="headingAnchor" id="H1696890027"><span class="h2">Benzodiazepines</span></p><p class="headingAnchor" id="H1072087027"><span class="h3">Midazolam</span><span class="headingEndMark"> — </span>Some clinicians administer <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> as an anxiolytic shortly before or after transport into the operating room (<a class="graphic graphic_table graphicRef106541" href="/d/graphic/106541.html" rel="external">table 2</a>). The primary mechanism of action is activation of the gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>) receptor, thereby inhibiting neurotransmission [<a href="#rid130">130</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages before and during induction</strong> – Dose-dependent potentially beneficial properties include [<a href="#rid131">131</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anxiolysis</p><p class="bulletIndent2"><span class="glyph">•</span>Amnesia</p><p class="bulletIndent2"><span class="glyph">•</span>Anticonvulsant properties</p><p class="bulletIndent2"><span class="glyph">•</span>Supplementation of sedation, which reduces dose requirements for the sedative-hypnotic induction agent [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential adverse effects</strong> – Dose-dependent potential adverse effects include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild systemic vasodilation and decreased cardiac output (CO), with consequent decrease in blood pressure (BP). This may be pronounced in patients with preexisting hypovolemia or vasodilation [<a href="#rid131">131</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory depression, particularly if an opioid is concurrently administered. Minute ventilation and the ventilatory response to carbon dioxide decrease, and apnea may occur with higher doses (≥0.15 mg/kg) [<a href="#rid131">131,132</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postoperative amnesia, prolonged drowsiness, and cognitive dysfunction, particularly in older patients [<a href="#rid133">133,134</a>]. Also, in a retrospective study of nearly three million patients undergoing total knee or hip arthroplasty, risk of in-hospital falls was increased if <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> was administered in the perioperative period [<a href="#rid134">134</a>]. (See  <a class="medical medical_review" href="/d/html/118691.html" rel="external">"Perioperative neurocognitive disorders in adults: Risk factors and mitigation strategies", section on 'Intravenous agents associated with higher risk'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pharyngeal dysfunction and discoordinated breathing and swallowing [<a href="#rid135">135,136</a>], </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Occasional unpredictable paradoxical reactions (eg, irritability, aggressiveness, delirium) [<a href="#rid137">137,138</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – For anxious adults, a <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> dose of 1 to 2 mg may be administered to alleviate anxiety. However, we avoid <strong>routine</strong> administration of benzodiazepine for premedication or during anesthetic induction, which is consistent with most protocols for enhanced recovery after surgery. (See  <a class="medical medical_review" href="/d/html/113724.html" rel="external">"Anesthetic management for enhanced recovery after major noncardiac surgery (ERAS)", section on 'Medications administered in the preoperative period'</a>.)</p><p></p><p class="headingAnchor" id="H3955418220"><span class="h3">Remimazolam</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="128915" href="/d/drug information/128915.html" rel="external">Remimazolam</a> is an ultra-short-acting benzodiazepine that is approved by the US Food and Drug Administration (FDA) for induction and maintenance of sedation in adults undergoing procedures lasting ≤30 minutes [<a href="#rid139">139</a>], and in Japan for use as a general anesthetic [<a href="#rid140">140,141</a>]. Although data describing safety and efficacy of remimazolam for induction of anesthesia are scant, this agent may prove useful to avoid the adverse effects of longer-acting benzodiazepines such as <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> [<a href="#rid142">142-145</a>]. (See <a class="local">'Midazolam'</a> above.)</p><p class="headingAnchor" id="H3792454773"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing considerations</strong> – Initial doses of intravenous (IV) sedative-hypnotic and adjuvant agents are individualized. Factors affecting dosing include adjusted body weight and other patient factors, dose-dependent adverse effects (eg, hypotension), and planned coadministration of adjuvant drugs. Supplemental doses are titrated if necessary. (See <a class="local">'Dosing considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sedative-hypnotic induction agents</strong> – <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a>, <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, and <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> are the IV sedative-hypnotic agents commonly used to induce general anesthesia (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> (See <a class="local">'Propofol'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Uses and advantages</strong> – <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> is selected for most hemodynamically stable patients because of its rapid onset and offset and beneficial antiemetic, antipruritic, bronchodilatory, and anticonvulsant properties.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Disadvantages and adverse effects</strong> – Dose-dependent hypotension and respiratory depression, pain on injection, and contamination risks.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dosing</strong> <strong>considerations</strong> – Induction dose is 1 to 2.5 mg/kg, but doses are reduced and titrated for some patients (eg, older age, hypovolemia, myocardial dysfunction) or circumstance (eg, coadministration of adjuvant anesthetic agents). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">Etomidate</a> (See <a class="local">'Etomidate'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Uses and advantages</strong> –<strong> </strong><a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">Etomidate</a> is often selected for patients with hemodynamic instability because it does not change blood pressure (BP), heart rate (HR), or cardiac output (CO).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Disadvantages and adverse effects</strong> – Transient acute adrenal insufficiency, higher incidence of postoperative nausea and vomiting, pain on injection, involuntary myoclonic movements, mild increases in airway resistance, and absence of analgesic effect.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dosing considerations</strong> – Induction dose is 0.15 to 0.3 mg/kg. To minimize inhibition of cortisol biosynthesis, repeated bolus doses are avoided.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a> (See <a class="local">'Ketamine'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Uses and advantages</strong> – <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a> may be selected for patients with impending or actual hypotension because administration typically increases BP, HR, and CO. Other advantages of ketamine include bronchodilation, profound analgesic properties, maintenance of airway reflexes and respiratory drive, and either IV or intramuscular (IM) routes of administration. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Disadvantages and adverse effects</strong> – Increases in BP and HR as well as increases in pulmonary artery pressure (PAP) that may be detrimental in patients with ischemic heart disease or systemic or pulmonary hypertension, increases in cerebral blood flow and intracranial pressure (ICP), and a high incidence of psychotomimetic effects.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dosing considerations</strong> – IV induction dose is 1 to 2 mg/kg IV. IM induction dose is 4 to 6 mg/kg. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">Methohexital</a> (See <a class="local">'Methohexital'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Uses and advantages</strong> – <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">Methohexital</a> is used almost exclusively as an induction agent for patients undergoing ECT procedures because it activates seizure foci. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Disadvantages and adverse effects</strong> – Activation of seizure foci is a disadvantage in patients with seizure disorder. Other adverse effects include dose-dependent BP decreases and respiratory depression, pain on injection, involuntary myoclonic movements, hiccups, exacerbation of acute intermittent porphyria, and rare anaphylactic reactions. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dosing considerations</strong> – Induction dose is 1 to 1.5 mg/kg. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjuvant agents</strong> – One or more adjuvant IV agents (eg, short-acting opioid, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, or benzodiazepine [<a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> or <a class="drug drug_general" data-topicid="128915" href="/d/drug information/128915.html" rel="external">remimazolam</a>] (<a class="graphic graphic_table graphicRef106541" href="/d/graphic/106541.html" rel="external">table 2</a>)) are often administered during induction to blunt the sympathetic stress response and cough reflex during laryngoscopy and intubation, minimize pain due to injection of irritating anesthetic induction agents, and supplement effects of the selected sedative-hypnotic agent to allow dose reduction. (See <a class="local">'Adjuvant agents'</a> above.)</p><p></p><p class="headingAnchor" id="H422776853"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Liza M Weavind, MBBCh, FCCM, MMHC, and Adam King, MD, who contributed to an earlier version of this topic review. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hendrickx JF, Eger EI 2nd, Sonner JM, Shafer SL. Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility. Anesth Analg 2008; 107:494.</a></li><li><a class="nounderline abstract_t">Smischney NJ, Beach ML, Loftus RW, et al. Ketamine/propofol admixture (ketofol) is associated with improved hemodynamics as an induction agent: a randomized, controlled trial. J Trauma Acute Care Surg 2012; 73:94.</a></li><li><a class="nounderline abstract_t">Smischney NJ, Nicholson WT, Brown DR, et al. Ketamine/propofol admixture vs etomidate for intubation in the critically ill: KEEP PACE Randomized clinical trial. J Trauma Acute Care Surg 2019; 87:883.</a></li><li class="breakAll">Bowdle TA. Can we prevent recall during anesthesia?. In: Evidence-Based Practice of Anesthesiology, 3rd ed, Fleisher L (Ed), Elsevier, Philadelphia 2013.</li><li><a class="nounderline abstract_t">Sabourdin N, Meniolle F, Chemam S, et al. Effect of Different Concentrations of Propofol Used as a Sole Anesthetic on Pupillary Diameter: A Randomized Trial. Anesth Analg 2020; 131:510.</a></li><li><a class="nounderline abstract_t">Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg 2020; 131:411.</a></li><li><a class="nounderline abstract_t">Eames WO, Rooke GA, Wu RS, Bishop MJ. Comparison of the effects of etomidate, propofol, and thiopental on respiratory resistance after tracheal intubation. Anesthesiology 1996; 84:1307.</a></li><li><a class="nounderline abstract_t">Conti G, Ferretti A, Tellan G, et al. Propofol induces bronchodilation in a patient mechanically ventilated for status asthmaticus. Intensive Care Med 1993; 19:305.</a></li><li><a class="nounderline abstract_t">Pizov R, Brown RH, Weiss YS, et al. Wheezing during induction of general anesthesia in patients with and without asthma. A randomized, blinded trial. Anesthesiology 1995; 82:1111.</a></li><li><a class="nounderline abstract_t">Pinaud M, Lelausque JN, Chetanneau A, et al. Effects of propofol on cerebral hemodynamics and metabolism in patients with brain trauma. Anesthesiology 1990; 73:404.</a></li><li><a class="nounderline abstract_t">Shafer SL. Advances in propofol pharmacokinetics and pharmacodynamics. J Clin Anesth 1993; 5:14S.</a></li><li><a class="nounderline abstract_t">Gray PA, Park GR, Cockshott ID, et al. Propofol metabolism in man during the anhepatic and reperfusion phases of liver transplantation. Xenobiotica 1992; 22:105.</a></li><li><a class="nounderline abstract_t">Smith I, White PF, Nathanson M, Gouldson R. Propofol. An update on its clinical use. Anesthesiology 1994; 81:1005.</a></li><li><a class="nounderline abstract_t">Takizawa D, Hiraoka H, Nakamura K, et al. Propofol concentrations during the anhepatic phase of living-related donor liver transplantation. Clin Pharmacol Ther 2004; 76:648.</a></li><li><a class="nounderline abstract_t">Takizawa D, Hiraoka H, Goto F, et al. Human kidneys play an important role in the elimination of propofol. Anesthesiology 2005; 102:327.</a></li><li><a class="nounderline abstract_t">Kuipers JA, Boer F, Olieman W, et al. First-pass lung uptake and pulmonary clearance of propofol: assessment with a recirculatory indocyanine green pharmacokinetic model. Anesthesiology 1999; 91:1780.</a></li><li><a class="nounderline abstract_t">Reekers M, Boer F, Vuyk J. Basic concepts of recirculatory pharmacokinetic modelling. Adv Exp Med Biol 2003; 523:19.</a></li><li><a class="nounderline abstract_t">Shafer SL. Shock values. Anesthesiology 2004; 101:567.</a></li><li><a class="nounderline abstract_t">Scheffer GJ, Ten Voorde BJ, Karemaker JM, et al. Effects of thiopentone, etomidate and propofol on beat-to-beat cardiovascular signals in man. Anaesthesia 1993; 48:849.</a></li><li><a class="nounderline abstract_t">Hug CC Jr, McLeskey CH, Nahrwold ML, et al. Hemodynamic effects of propofol: data from over 25,000 patients. Anesth Analg 1993; 77:S21.</a></li><li><a class="nounderline abstract_t">Bein B, Renner J, Caliebe D, et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesth Analg 2005; 100:610.</a></li><li><a class="nounderline abstract_t">Ebert TJ. Sympathetic and hemodynamic effects of moderate and deep sedation with propofol in humans. Anesthesiology 2005; 103:20.</a></li><li><a class="nounderline abstract_t">Masuda T, Tomiyama Y, Kitahata H, et al. Propofol inhibits volume-sensitive chloride channels in human coronary artery smooth muscle cells. Anesth Analg 2003; 97:657.</a></li><li><a class="nounderline abstract_t">Euasobhon P, Dej-Arkom S, Siriussawakul A, et al. Lidocaine for reducing propofol-induced pain on induction of anaesthesia in adults. Cochrane Database Syst Rev 2016; 2:CD007874.</a></li><li><a class="nounderline abstract_t">Picard P, Tramèr MR. Prevention of pain on injection with propofol: a quantitative systematic review. Anesth Analg 2000; 90:963.</a></li><li><a class="nounderline abstract_t">Jalota L, Kalira V, George E, et al. Prevention of pain on injection of propofol: systematic review and meta-analysis. BMJ 2011; 342:d1110.</a></li><li><a class="nounderline abstract_t">Muller AE, Huisman I, Roos PJ, et al. Outbreak of severe sepsis due to contaminated propofol: lessons to learn. J Hosp Infect 2010; 76:225.</a></li><li><a class="nounderline abstract_t">Asserhøj LL, Mosbech H, Krøigaard M, Garvey LH. No evidence for contraindications to the use of propofol in adults allergic to egg, soy or peanut†. Br J Anaesth 2016; 116:77.</a></li><li><a class="nounderline abstract_t">Vinik HR, Bradley EL Jr, Kissin I. Triple anesthetic combination: propofol-midazolam-alfentanil. Anesth Analg 1994; 78:354.</a></li><li><a class="nounderline abstract_t">Absalom AR, Mani V, De Smet T, Struys MM. Pharmacokinetic models for propofol--defining and illuminating the devil in the detail. Br J Anaesth 2009; 103:26.</a></li><li><a class="nounderline abstract_t">Khan KS, Hayes I, Buggy DJ. Pharmacology of anaesthetic agents I: intravenous induction agents. Contin Educ Anaesth Crit Care Pain 2014; 14:100.</a></li><li><a class="nounderline abstract_t">Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992; 76:334.</a></li><li><a class="nounderline abstract_t">Shafer SL, Stanski DR. Improving the clinical utility of anesthetic drug pharmacokinetics. Anesthesiology 1992; 76:327.</a></li><li class="breakAll">Drug insert for propofol: FDA-approved dose http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019627s046lbl.pdf (Accessed on April 26, 2016).</li><li><a class="nounderline abstract_t">Kirkpatrick T, Cockshott ID, Douglas EJ, Nimmo WS. Pharmacokinetics of propofol (diprivan) in elderly patients. Br J Anaesth 1988; 60:146.</a></li><li><a class="nounderline abstract_t">Das S, Forrest K, Howell S. General anaesthesia in elderly patients with cardiovascular disorders: choice of anaesthetic agent. Drugs Aging 2010; 27:265.</a></li><li><a class="nounderline abstract_t">Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology 2011; 114:695.</a></li><li><a class="nounderline abstract_t">Holdcroft A, Morgan M, Whitwam JG, Lumley J. Effect of dose and premedication on induction complications with etomidate. Br J Anaesth 1976; 48:199.</a></li><li><a class="nounderline abstract_t">Fruergaard K, Jenstrup M, Schierbeck J, Wiberg-Jørgensen F. Total intravenous anaesthesia with propofol or etomidate. Eur J Anaesthesiol 1991; 8:385.</a></li><li class="breakAll">Paul F. White and Matthew R. Eng. Intravenous Anesthetics. In: Clinical Anesthesia, Seventh, Paul G. Barash (Ed), Lippincott Williams &amp;  Wilkins, Philadelphia 2013. p.478-500.</li><li><a class="nounderline abstract_t">Hüter L, Schreiber T, Gugel M, Schwarzkopf K. Low-dose intravenous midazolam reduces etomidate-induced myoclonus: a prospective, randomized study in patients undergoing elective cardioversion. Anesth Analg 2007; 105:1298.</a></li><li><a class="nounderline abstract_t">Hueter L, Schwarzkopf K, Simon M, et al. Pretreatment with sufentanil reduces myoclonus after etomidate. Acta Anaesthesiol Scand 2003; 47:482.</a></li><li><a class="nounderline abstract_t">Stockham RJ, Stanley TH, Pace NL, et al. Fentanyl pretreatment modifies anaesthetic induction with etomidate. Anaesth Intensive Care 1988; 16:171.</a></li><li><a class="nounderline abstract_t">Schwarzkopf KR, Hueter L, Simon M, Fritz HG. Midazolam pretreatment reduces etomidate-induced myoclonic movements. Anaesth Intensive Care 2003; 31:18.</a></li><li><a class="nounderline abstract_t">Cohan P, Wang C, McArthur DL, et al. Acute secondary adrenal insufficiency after traumatic brain injury: a prospective study. Crit Care Med 2005; 33:2358.</a></li><li><a class="nounderline abstract_t">den Brinker M, Joosten KF, Liem O, et al. Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab 2005; 90:5110.</a></li><li><a class="nounderline abstract_t">Jackson WL Jr. Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock?: a critical appraisal. Chest 2005; 127:1031.</a></li><li><a class="nounderline abstract_t">Schenarts CL, Burton JH, Riker RR. Adrenocortical dysfunction following etomidate induction in emergency department patients. Acad Emerg Med 2001; 8:1.</a></li><li><a class="nounderline abstract_t">Basciani RM, Rindlisbacher A, Begert E, et al. Anaesthetic induction with etomidate in cardiac surgery: A randomised controlled trial. Eur J Anaesthesiol 2016; 33:417.</a></li><li><a class="nounderline abstract_t">Bruder EA, Ball IM, Ridi S, et al. Single induction dose of etomidate versus other induction agents for endotracheal intubation in critically ill patients. Cochrane Database Syst Rev 2015; 1:CD010225.</a></li><li><a class="nounderline abstract_t">Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999; 54:861.</a></li><li><a class="nounderline abstract_t">Fragen RJ, Weiss HW, Molteni A. The effect of propofol on adrenocortical steroidogenesis: a comparative study with etomidate and thiopental. Anesthesiology 1987; 66:839.</a></li><li><a class="nounderline abstract_t">Jameson P, Desborough JP, Bryant AE, Hall GM. The effect of cortisol suppression on interleukin-6 and white blood cell responses to surgery. Acta Anaesthesiol Scand 1997; 41:304.</a></li><li><a class="nounderline abstract_t">Malerba G, Romano-Girard F, Cravoisy A, et al. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005; 31:388.</a></li><li><a class="nounderline abstract_t">Komatsu R, You J, Mascha EJ, et al. Anesthetic induction with etomidate, rather than propofol, is associated with increased 30-day mortality and cardiovascular morbidity after noncardiac surgery. Anesth Analg 2013; 117:1329.</a></li><li><a class="nounderline abstract_t">Heinrich S, Schmidt J, Ackermann A, et al. Comparison of clinical outcome variables in patients with and without etomidate-facilitated anesthesia induction ahead of major cardiac surgery: a retrospective analysis. Crit Care 2014; 18:R150.</a></li><li><a class="nounderline abstract_t">Wagner CE, Bick JS, Johnson D, et al. Etomidate use and postoperative outcomes among cardiac surgery patients. Anesthesiology 2014; 120:579.</a></li><li><a class="nounderline abstract_t">Gu WJ, Wang F, Tang L, Liu JC. Single-dose etomidate does not increase mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials and observational studies. Chest 2015; 147:335.</a></li><li><a class="nounderline abstract_t">Matchett G, Gasanova I, Riccio CA, et al. Etomidate versus ketamine for emergency endotracheal intubation: a randomized clinical trial. Intensive Care Med 2022; 48:78.</a></li><li><a class="nounderline abstract_t">Chan CM, Mitchell AL, Shorr AF. Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*. Crit Care Med 2012; 40:2945.</a></li><li><a class="nounderline abstract_t">Komatsu R, You J, Rajan S, et al. Steroid administration after anaesthetic induction with etomidate does not reduce in-hospital mortality or cardiovascular morbidity after non-cardiac surgery. Br J Anaesth 2018; 120:501.</a></li><li><a class="nounderline abstract_t">Bergen JM, Smith DC. A review of etomidate for rapid sequence intubation in the emergency department. J Emerg Med 1997; 15:221.</a></li><li><a class="nounderline abstract_t">Kaneda K, Yamashita S, Woo S, Han TH. Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. J Clin Pharmacol 2011; 51:482.</a></li><li><a class="nounderline abstract_t">Van Hamme MJ, Ghoneim MM, Ambre JJ. Pharmacokinetics of etomidate, a new intravenous anesthetic. Anesthesiology 1978; 49:274.</a></li><li class="breakAll">Perouansky M, Hemmings HC. Intravenous anaesthetic agents. In: Foundations of Anesthesia, 2nd ed, Hemmings HC, Hopkins PM (Eds), Elsevier, Philadelphia 2006. p.295.</li><li><a class="nounderline abstract_t">Gray LD, Morris C. The principles and conduct of anaesthesia for emergency surgery. Anaesthesia 2013; 68 Suppl 1:14.</a></li><li><a class="nounderline abstract_t">Morris C, Perris A, Klein J, Mahoney P. Anaesthesia in haemodynamically compromised emergency patients: does ketamine represent the best choice of induction agent? Anaesthesia 2009; 64:532.</a></li><li><a class="nounderline abstract_t">Pandit JJ. Intravenous anaesthetic agents. Anaesthesia and Intensive Care Medicine 2007; 9:154.</a></li><li><a class="nounderline abstract_t">Rogers R, Wise RG, Painter DJ, et al. An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging. Anesthesiology 2004; 100:292.</a></li><li><a class="nounderline abstract_t">Corssen G, Domino EF. Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 1966; 45:29.</a></li><li><a class="nounderline abstract_t">Olofsen E, Kamp J, Henthorn TK, et al. Ketamine Psychedelic and Antinociceptive Effects Are Connected. Anesthesiology 2022; 136:792.</a></li><li><a class="nounderline abstract_t">Kung J, Meisner RC, Berg S, Ellis DB. Ketamine: A review of an established yet often underappreciated medication. APSF Newsletter 2020; June issue:64.</a></li><li><a class="nounderline abstract_t">Chen RM, Chen TL, Lin YL, et al. Ketamine reduces nitric oxide biosynthesis in human umbilical vein endothelial cells by down-regulating endothelial nitric oxide synthase expression and intracellular calcium levels. Crit Care Med 2005; 33:1044.</a></li><li><a class="nounderline abstract_t">Corssen G, Gutierrez J, Reves JG, Huber FC Jr. Ketamine in the anesthetic management of asthmatic patients. Anesth Analg 1972; 51:588.</a></li><li><a class="nounderline abstract_t">Denmark TK, Crane HA, Brown L. Ketamine to avoid mechanical ventilation in severe pediatric asthma. J Emerg Med 2006; 30:163.</a></li><li><a class="nounderline abstract_t">Eikermann M, Grosse-Sundrup M, Zaremba S, et al. Ketamine activates breathing and abolishes the coupling between loss of consciousness and upper airway dilator muscle dysfunction. Anesthesiology 2012; 116:35.</a></li><li><a class="nounderline abstract_t">Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006; :CD004603.</a></li><li><a class="nounderline abstract_t">Loftus RW, Yeager MP, Clark JA, et al. Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. Anesthesiology 2010; 113:639.</a></li><li><a class="nounderline abstract_t">McGuinness SK, Wasiak J, Cleland H, et al. A systematic review of ketamine as an analgesic agent in adult burn injuries. Pain Med 2011; 12:1551.</a></li><li><a class="nounderline abstract_t">Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005; 103:147.</a></li><li><a class="nounderline abstract_t">Långsjö JW, Kaisti KK, Aalto S, et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003; 99:614.</a></li><li><a class="nounderline abstract_t">Hanouz JL, Persehaye E, Zhu L, et al. The inotropic and lusitropic effects of ketamine in isolated human atrial myocardium: the effect of adrenoceptor blockade. Anesth Analg 2004; 99:1689.</a></li><li><a class="nounderline abstract_t">Hanouz JL, Zhu L, Persehaye E, et al. Ketamine preconditions isolated human right atrial myocardium: roles of adenosine triphosphate-sensitive potassium channels and adrenoceptors. Anesthesiology 2005; 102:1190.</a></li><li><a class="nounderline abstract_t">Gooding JM, Dimick AR, Tavakoli M, Corssen G. A physiologic analysis of cardiopulmonary responses to ketamine anesthesia in noncardiac patients. Anesth Analg 1977; 56:813.</a></li><li><a class="nounderline abstract_t">Cheng DC. The drug addicted patient. Can J Anaesth 1997; 44:R101.</a></li><li><a class="nounderline abstract_t">Weiskopf RB, Bogetz MS, Roizen MF, Reid IA. Cardiovascular and metabolic sequelae of inducing anesthesia with ketamine or thiopental in hypovolemic swine. Anesthesiology 1984; 60:214.</a></li><li><a class="nounderline abstract_t">Bowdle TA, Radant AD, Cowley DS, et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 1998; 88:82.</a></li><li><a class="nounderline abstract_t">Kleinloog D, Uit den Boogaard A, Dahan A, et al. Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers. J Psychopharmacol 2015; 29:401.</a></li><li><a class="nounderline abstract_t">Kamp J, Olofsen E, Henthorn TK, et al. Ketamine Pharmacokinetics. Anesthesiology 2020; 133:1192.</a></li><li><a class="nounderline abstract_t">Grace RF. The effect of variable-dose diazepam on dreaming and emergence phenomena in 400 cases of ketamine-fentanyl anaesthesia. Anaesthesia 2003; 58:904.</a></li><li><a class="nounderline abstract_t">Gardner AE, Dannemiller FJ, Dean D. Intracranial cerebrospinal fluid pressure in man during ketamine anesthesia. Anesth Analg 1972; 51:741.</a></li><li><a class="nounderline abstract_t">Långsjö JW, Salmi E, Kaisti KK, et al. Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology 2004; 100:1065.</a></li><li><a class="nounderline abstract_t">Hudetz JA, Pagel PS. Neuroprotection by ketamine: a review of the experimental and clinical evidence. J Cardiothorac Vasc Anesth 2010; 24:131.</a></li><li><a class="nounderline abstract_t">Barreto Chang OL, Kreuzer M, Morgen DF, et al. Ketamine-Associated Intraoperative Electroencephalographic Signatures of Elderly Patients With and Without Preoperative Cognitive Impairment. Anesth Analg 2022; 135:683.</a></li><li><a class="nounderline abstract_t">Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002; 95:114.</a></li><li><a class="nounderline abstract_t">Herd DW, Anderson BJ, Keene NA, Holford NH. Investigating the pharmacodynamics of ketamine in children. Paediatr Anaesth 2008; 18:36.</a></li><li><a class="nounderline abstract_t">White PF, Schüttler J, Shafer A, et al. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth 1985; 57:197.</a></li><li><a class="nounderline abstract_t">Clements JA, Nimmo WS. Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 1981; 53:27.</a></li><li><a class="nounderline abstract_t">Cohen ML, Trevor AJ. On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. J Pharmacol Exp Ther 1974; 189:351.</a></li><li><a class="nounderline abstract_t">Grant IS, Nimmo WS, McNicol LR, Clements JA. Ketamine disposition in children and adults. Br J Anaesth 1983; 55:1107.</a></li><li><a class="nounderline abstract_t">Taylor C, Stoelting VK. Methohexital sodium - a new ultrashort acting barbiturate. Anesthesiology 1960; 21:29.</a></li><li><a class="nounderline abstract_t">Harrison GG, Meissner PN, Hift RJ. Anaesthesia for the porphyric patient. Anaesthesia 1993; 48:417.</a></li><li><a class="nounderline abstract_t">Kelly HE, Shaw GM, Brett CN, et al. The effect of titrated fentanyl on suppressed cough reflex in healthy adult volunteers. Anaesthesia 2016; 71:529.</a></li><li><a class="nounderline abstract_t">Chung KS, Sinatra RS, Halevy JD, et al. A comparison of fentanyl, esmolol, and their combination for blunting the haemodynamic responses during rapid-sequence induction. Can J Anaesth 1992; 39:774.</a></li><li><a class="nounderline abstract_t">Cork RC, Weiss JL, Hameroff SR, Bentley J. Fentanyl preloading for rapid-sequence induction of anesthesia. Anesth Analg 1984; 63:60.</a></li><li><a class="nounderline abstract_t">Dahlgren N, Messeter K. Treatment of stress response to laryngoscopy and intubation with fentanyl. Anaesthesia 1981; 36:1022.</a></li><li><a class="nounderline abstract_t">El-Radaideh KM. [Effect of pretreatment with lidocaine, intravenous paracetamol and lidocaine-fentanyl on propofol injection pain. Comparative study. Rev Bras Anestesiol 2007; 57:32.</a></li><li><a class="nounderline abstract_t">Prabhakar H, Singh GP, Ali Z, et al. Pharmacological and non-pharmacological interventions for reducing rocuronium bromide induced pain on injection in children and adults. Cochrane Database Syst Rev 2016; 2:CD009346.</a></li><li><a class="nounderline abstract_t">Aouad MT, Siddik-Sayyid SM, Al-Alami AA, Baraka AS. Multimodal analgesia to prevent propofol-induced pain: pretreatment with remifentanil and lidocaine versus remifentanil or lidocaine alone. Anesth Analg 2007; 104:1540.</a></li><li><a class="nounderline abstract_t">Rahman Al-Refai A, Al-Mujadi H, Petrova Ivanova M, et al. Prevention of pain on injection of propofol: a comparison of remifentanil with alfentanil in children. Minerva Anestesiol 2007; 73:219.</a></li><li><a class="nounderline abstract_t">Kazama T, Ikeda K, Morita K. The pharmacodynamic interaction between propofol and fentanyl with respect to the suppression of somatic or hemodynamic responses to skin incision, peritoneum incision, and abdominal wall retraction. Anesthesiology 1998; 89:894.</a></li><li><a class="nounderline abstract_t">Smith C, McEwan AI, Jhaveri R, et al. The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision. Anesthesiology 1994; 81:820.</a></li><li><a class="nounderline abstract_t">Short TG, Plummer JL, Chui PT. Hypnotic and anaesthetic interactions between midazolam, propofol and alfentanil. Br J Anaesth 1992; 69:162.</a></li><li><a class="nounderline abstract_t">Kazama T, Ikeda K, Morita K. Reduction by fentanyl of the Cp50 values of propofol and hemodynamic responses to various noxious stimuli. Anesthesiology 1997; 87:213.</a></li><li><a class="nounderline abstract_t">Van Aken H, Meinshausen E, Prien T, et al. The influence of fentanyl and tracheal intubation on the hemodynamic effects of anesthesia induction with propofol/N2O in humans. Anesthesiology 1988; 68:157.</a></li><li><a class="nounderline abstract_t">STEINHAUS JE, GASKIN L. A study of intravenous lidocaine as a suppressant of cough reflex. Anesthesiology 1963; 24:285.</a></li><li><a class="nounderline abstract_t">Aouad MT, Sayyid SS, Zalaket MI, Baraka AS. Intravenous lidocaine as adjuvant to sevoflurane anesthesia for endotracheal intubation in children. Anesth Analg 2003; 96:1325.</a></li><li><a class="nounderline abstract_t">Davidson JA, Gillespie JA. Tracheal intubation after induction of anaesthesia with propofol, alfentanil and i.v. lignocaine. Br J Anaesth 1993; 70:163.</a></li><li><a class="nounderline abstract_t">Jakobsen CJ, Ahlburg P, Holdgård HO, et al. Comparison of intravenous and topical lidocaine as a suppressant of coughing after bronchoscopy during general anesthesia. Acta Anaesthesiol Scand 1991; 35:238.</a></li><li><a class="nounderline abstract_t">Lin CS, Sun WZ, Chan WH, et al. Intravenous lidocaine and ephedrine, but not propofol, suppress fentanyl-induced cough. Can J Anaesth 2004; 51:654.</a></li><li><a class="nounderline abstract_t">Nishino T, Hiraga K, Sugimori K. Effects of i.v. lignocaine on airway reflexes elicited by irritation of the tracheal mucosa in humans anaesthetized with enflurane. Br J Anaesth 1990; 64:682.</a></li><li><a class="nounderline abstract_t">Pandey CK, Raza M, Ranjan R, et al. Intravenous lidocaine suppresses fentanyl-induced coughing: a double-blind, prospective, randomized placebo-controlled study. Anesth Analg 2004; 99:1696.</a></li><li><a class="nounderline abstract_t">Pandey CK, Raza M, Ranjan R, et al. Intravenous lidocaine 0.5 mg.kg-1 effectively suppresses fentanyl-induced cough. Can J Anaesth 2005; 52:172.</a></li><li><a class="nounderline abstract_t">Warner LO, Balch DR, Davidson PJ. Is intravenous lidocaine an effective adjuvant for endotracheal intubation in children undergoing induction of anesthesia with halothane-nitrous oxide? J Clin Anesth 1997; 9:270.</a></li><li><a class="nounderline abstract_t">Yukioka H, Hayashi M, Terai T, Fujimori M. Intravenous lidocaine as a suppressant of coughing during tracheal intubation in elderly patients. Anesth Analg 1993; 77:309.</a></li><li><a class="nounderline abstract_t">Adamzik M, Groeben H, Farahani R, et al. Intravenous lidocaine after tracheal intubation mitigates bronchoconstriction in patients with asthma. Anesth Analg 2007; 104:168.</a></li><li><a class="nounderline abstract_t">Chang HY, Togias A, Brown RH. The effects of systemic lidocaine on airway tone and pulmonary function in asthmatic subjects. Anesth Analg 2007; 104:1109.</a></li><li><a class="nounderline abstract_t">Maslow AD, Regan MM, Israel E, et al. Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma. Anesthesiology 2000; 93:1198.</a></li><li><a class="nounderline abstract_t">Xing J, Liang L, Zhou S, et al. Intravenous Lidocaine Alleviates the Pain of Propofol Injection by Local Anesthetic and Central Analgesic Effects. Pain Med 2018; 19:598.</a></li><li><a class="nounderline abstract_t">Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008; 118:69.</a></li><li><a class="nounderline abstract_t">Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology 1985; 62:310.</a></li><li><a class="nounderline abstract_t">Forster A, Gardaz JP, Suter PM, Gemperle M. Respiratory depression by midazolam and diazepam. Anesthesiology 1980; 53:494.</a></li><li><a class="nounderline abstract_t">Rogers JF, Morrison AL, Nafziger AN, et al. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics. Clin Pharmacol Ther 2002; 72:711.</a></li><li><a class="nounderline abstract_t">Athanassoglou V, Cozowicz C, Zhong H, et al. Association of perioperative midazolam use and complications: a population-based analysis. Reg Anesth Pain Med 2022; 47:228.</a></li><li><a class="nounderline abstract_t">Hårdemark Cedborg AI, Sundman E, Bodén K, et al. Effects of morphine and midazolam on pharyngeal function, airway protection, and coordination of breathing and swallowing in healthy adults. Anesthesiology 2015; 122:1253.</a></li><li><a class="nounderline abstract_t">Petroianni A, Ceccarelli D, Conti V, Terzano C. Aspiration pneumonia. Pathophysiological aspects, prevention and management. A review. Panminerva Med 2006; 48:231.</a></li><li><a class="nounderline abstract_t">Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy 2004; 24:1177.</a></li><li><a class="nounderline abstract_t">Lepousé C, Lautner CA, Liu L, et al. Emergence delirium in adults in the post-anaesthesia care unit. Br J Anaesth 2006; 96:747.</a></li><li><a class="nounderline abstract_t">Remimazolam (Byfavo) for short-term procedural sedation. Med Lett Drugs Ther 2022; 64:26.</a></li><li><a class="nounderline abstract_t">Masui K. Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!! J Anesth 2020; 34:479.</a></li><li><a class="nounderline abstract_t">Keam SJ. Remimazolam: First Approval. Drugs 2020; 80:625.</a></li><li><a class="nounderline abstract_t">Hirata N, Hayamizu K, Yamakage M. How to administer remimazolam for anesthesia induction. J Anesth 2020; 34:962.</a></li><li><a class="nounderline abstract_t">Dai G, Pei L, Duan F, et al. Safety and efficacy of remimazolam compared with propofol in induction of general anesthesia. Minerva Anestesiol 2021; 87:1073.</a></li><li><a class="nounderline abstract_t">Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020; 34:543.</a></li><li><a class="nounderline abstract_t">Zhou J, Leonowens C, Ivaturi VD, et al. Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth 2020; 66:109899.</a></li></ol></div><div id="topicVersionRevision">Topic 94533 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633028" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22743378" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ketamine/propofol admixture (ketofol) is associated with improved hemodynamics as an induction agent: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31335755" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ketamine/propofol admixture vs etomidate for intubation in the critically ill: KEEP PACE Randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31335755" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ketamine/propofol admixture vs etomidate for intubation in the critically ill: KEEP PACE Randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31490817" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of Different Concentrations of Propofol Used as a Sole Anesthetic on Pupillary Diameter: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32467512" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8669670" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of the effects of etomidate, propofol, and thiopental on respiratory resistance after tracheal intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8408944" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Propofol induces bronchodilation in a patient mechanically ventilated for status asthmaticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7741285" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Wheezing during induction of general anesthesia in patients with and without asthma. A randomized, blinded trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2118315" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effects of propofol on cerebral hemodynamics and metabolism in patients with brain trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8292364" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Advances in propofol pharmacokinetics and pharmacodynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1615701" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Propofol metabolism in man during the anhepatic and reperfusion phases of liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7943815" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Propofol. An update on its clinical use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592336" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Propofol concentrations during the anhepatic phase of living-related donor liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681947" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Human kidneys play an important role in the elimination of propofol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10598622" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : First-pass lung uptake and pulmonary clearance of propofol: assessment with a recirculatory indocyanine green pharmacokinetic model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15088836" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Basic concepts of recirculatory pharmacokinetic modelling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15329579" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Shock values.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8238825" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effects of thiopentone, etomidate and propofol on beat-to-beat cardiovascular signals in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214693" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hemodynamic effects of propofol: data from over 25,000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728039" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983452" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sympathetic and hemodynamic effects of moderate and deep sedation with propofol in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12933379" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Propofol inhibits volume-sensitive chloride channels in human coronary artery smooth muscle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888026" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lidocaine for reducing propofol-induced pain on induction of anaesthesia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735808" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prevention of pain on injection with propofol: a quantitative systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406529" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevention of pain on injection of propofol: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20692067" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Outbreak of severe sepsis due to contaminated propofol: lessons to learn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26675952" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : No evidence for contraindications to the use of propofol in adults allergic to egg, soy or peanut†.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8311290" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Triple anesthetic combination: propofol-midazolam-alfentanil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19520702" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pharmacokinetic models for propofol--defining and illuminating the devil in the detail.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pharmacology of anaesthetic agents I: intravenous induction agents</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1539843" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1539841" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Improving the clinical utility of anesthetic drug pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1539841" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Improving the clinical utility of anesthetic drug pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3257879" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pharmacokinetics of propofol (diprivan) in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20359259" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : General anaesthesia in elderly patients with cardiovascular disorders: choice of anaesthetic agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21263301" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical and molecular pharmacology of etomidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1259885" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of dose and premedication on induction complications with etomidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1935927" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Total intravenous anaesthesia with propofol or etomidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1935927" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Total intravenous anaesthesia with propofol or etomidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17959958" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Low-dose intravenous midazolam reduces etomidate-induced myoclonus: a prospective, randomized study in patients undergoing elective cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694150" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pretreatment with sufentanil reduces myoclonus after etomidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3394909" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fentanyl pretreatment modifies anaesthetic induction with etomidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12635389" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Midazolam pretreatment reduces etomidate-induced myoclonic movements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16215393" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acute secondary adrenal insufficiency after traumatic brain injury: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985474" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764790" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock?: a critical appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136139" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Adrenocortical dysfunction following etomidate induction in emergency department patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26914224" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Anaesthetic induction with etomidate in cardiac surgery: A randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25568981" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Single induction dose of etomidate versus other induction agents for endotracheal intubation in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460557" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adrenocortical function in critically ill patients 24 h after a single dose of etomidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3035963" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The effect of propofol on adrenocortical steroidogenesis: a comparative study with etomidate and thiopental.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062617" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The effect of cortisol suppression on interleukin-6 and white blood cell responses to surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15703896" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24257383" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Anesthetic induction with etomidate, rather than propofol, is associated with increased 30-day mortality and cardiovascular morbidity after noncardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25015112" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of clinical outcome variables in patients with and without etomidate-facilitated anesthesia induction ahead of major cardiac surgery: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24296761" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Etomidate use and postoperative outcomes among cardiac surgery patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25255427" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Single-dose etomidate does not increase mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials and observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34904190" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Etomidate versus ketamine for emergency endotracheal intubation: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22971586" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29452806" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Steroid administration after anaesthetic induction with etomidate does not reduce in-hospital mortality or cardiovascular morbidity after non-cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9144065" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A review of etomidate for rapid sequence intubation in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498288" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/697083" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pharmacokinetics of etomidate, a new intravenous anesthetic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/697083" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pharmacokinetics of etomidate, a new intravenous anesthetic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23210553" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The principles and conduct of anaesthesia for emergency surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19413824" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Anaesthesia in haemodynamically compromised emergency patients: does ketamine represent the best choice of induction agent?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Intravenous anaesthetic agents</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14739803" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5325977" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35188952" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Ketamine Psychedelic and Antinociceptive Effects Are Connected.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Ketamine: A review of an established yet often underappreciated medication</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15891334" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ketamine reduces nitric oxide biosynthesis in human umbilical vein endothelial cells by down-regulating endothelial nitric oxide synthase expression and intracellular calcium levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5064793" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Ketamine in the anesthetic management of asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567251" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Ketamine to avoid mechanical ventilation in severe pediatric asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22108392" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ketamine activates breathing and abolishes the coupling between loss of consciousness and upper airway dilator muscle dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437490" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Perioperative ketamine for acute postoperative pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693876" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880111" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A systematic review of ketamine as an analgesic agent in adult burn injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983467" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12960545" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15562055" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The inotropic and lusitropic effects of ketamine in isolated human atrial myocardium: the effect of adrenoceptor blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15915032" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Ketamine preconditions isolated human right atrial myocardium: roles of adenosine triphosphate-sensitive potassium channels and adrenoceptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/563185" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A physiologic analysis of cardiopulmonary responses to ketamine anesthesia in noncardiac patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196844" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The drug addicted patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6696255" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cardiovascular and metabolic sequelae of inducing anesthesia with ketamine or thiopental in hypovolemic swine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9447860" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25693889" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32997732" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ketamine Pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12911367" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The effect of variable-dose diazepam on dreaming and emergence phenomena in 400 cases of ketamine-fentanyl anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Intracranial cerebrospinal fluid pressure in man during ketamine anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114201" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19640746" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Neuroprotection by ketamine: a review of the experimental and clinical evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35051953" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Ketamine-Associated Intraoperative Electroencephalographic Signatures of Elderly Patients With and Without Preoperative Cognitive Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12088953" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Small-dose ketamine improves the postoperative state of depressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18095964" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Investigating the pharmacodynamics of ketamine in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3970799" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Comparative pharmacology of the ketamine isomers. Studies in volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7459184" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pharmacokinetics and analgesic effect of ketamine in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4829218" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6639827" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Ketamine disposition in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Methohexital sodium - a new ultrashort acting barbiturate</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8292131" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Anaesthesia for the porphyric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26919658" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The effect of titrated fentanyl on suppressed cough reflex in healthy adult volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1363221" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A comparison of fentanyl, esmolol, and their combination for blunting the haemodynamic responses during rapid-sequence induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6318605" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Fentanyl preloading for rapid-sequence induction of anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7032347" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Treatment of stress response to laryngoscopy and intubation with fentanyl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19468616" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : [Effect of pretreatment with lidocaine, intravenous paracetamol and lidocaine-fentanyl on propofol injection pain. Comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26871982" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Pharmacological and non-pharmacological interventions for reducing rocuronium bromide induced pain on injection in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17513655" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Multimodal analgesia to prevent propofol-induced pain: pretreatment with remifentanil and lidocaine versus remifentanil or lidocaine alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17159759" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Prevention of pain on injection of propofol: a comparison of remifentanil with alfentanil in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778007" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The pharmacodynamic interaction between propofol and fentanyl with respect to the suppression of somatic or hemodynamic responses to skin incision, peritoneum incision, and abdominal wall retraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7943832" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1389820" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Hypnotic and anaesthetic interactions between midazolam, propofol and alfentanil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9286884" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Reduction by fentanyl of the Cp50 values of propofol and hemodynamic responses to various noxious stimuli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3257362" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The influence of fentanyl and tracheal intubation on the hemodynamic effects of anesthesia induction with propofol/N2O in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13983769" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : A study of intravenous lidocaine as a suppressant of cough reflex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707127" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Intravenous lidocaine as adjuvant to sevoflurane anesthesia for endotracheal intubation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8435260" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Tracheal intubation after induction of anaesthesia with propofol, alfentanil and i.v. lignocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2038931" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Comparison of intravenous and topical lidocaine as a suppressant of coughing after bronchoscopy during general anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15310631" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Intravenous lidocaine and ephedrine, but not propofol, suppress fentanyl-induced cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2116157" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effects of i.v. lignocaine on airway reflexes elicited by irritation of the tracheal mucosa in humans anaesthetized with enflurane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15562056" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Intravenous lidocaine suppresses fentanyl-induced coughing: a double-blind, prospective, randomized placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15684258" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Intravenous lidocaine 0.5 mg.kg-1 effectively suppresses fentanyl-induced cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9195347" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Is intravenous lidocaine an effective adjuvant for endotracheal intubation in children undergoing induction of anesthesia with halothane-nitrous oxide?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8346830" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Intravenous lidocaine as a suppressant of coughing during tracheal intubation in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17179265" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Intravenous lidocaine after tracheal intubation mitigates bronchoconstriction in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17456660" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : The effects of systemic lidocaine on airway tone and pulmonary function in asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11046206" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28525614" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Intravenous Lidocaine Alleviates the Pain of Propofol Injection by Local Anesthetic and Central Analgesic Effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18384456" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3156545" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Midazolam: pharmacology and uses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7457966" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Respiratory depression by midazolam and diazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12496752" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35022262" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Association of perioperative midazolam use and complications: a population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25853450" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Effects of morphine and midazolam on pharyngeal function, airway protection, and coordination of breathing and swallowing in healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215795" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Aspiration pneumonia. Pathophysiological aspects, prevention and management. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15460178" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Paradoxical reactions to benzodiazepines: literature review and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16670111" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Emergence delirium in adults in the post-anaesthesia care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Remimazolam (Byfavo) for short-term procedural sedation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32157465" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32274703" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Remimazolam: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33048211" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : How to administer remimazolam for anesthesia induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34263581" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Safety and efficacy of remimazolam compared with propofol in induction of general anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32417976" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32585566" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
